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T
ransition to Medicare Part D affected not only 35.4 million
elderly enrollees but also 6.4 million younger enrollees with
disabilities, 2.5 million of whom have low incomes and pre-
viously obtained medications through Medicaid. Because
Part D was conceived primarily as a benefit for elders, we sought to
examine its effects on a dually eligible, younger group of beneficiaries
who have significantly different, more expensive, and often unstable
health conditions.
ANTICIPATED ISSUES FOR 
DUAL ELIGIBLES
CMS Preemptive Policies
The Centers for Medicare & Medicaid Services (CMS) instituted
policies intended to “mitigate the risks and complications associated with
an interruption of therapy” for dual eligibles taking certain categories of
drugs.1 To ensure continuous coverage, CMS required that dual eligibles
be automatically assigned to a Part D plan but permitted them to change
plans monthly.
CMS required formularies to cover all or substantially all medications
within 6 drug classes: antidepressants, antipsychotics, anticonvulsants,
anticancer drugs, immunosuppressants, and antiretrovirals for treating
HIV/AIDS.2 CMS prohibited Part D plan sponsors from implementing prior
authorization or step therapy requirements intended to “steer beneficiaries to
preferred alternatives within these classes for enrollees who are currently
taking a drug.”1 Regulations stipulate that patients stabilized on an antide-
pressant or antipsychotic drug before switching to Part D “should not be sub-
ject to utilization management strategies, such as prior authorization or
requirements to first fail a preferred product (fail first), to continue therapy.”3
Studies of Part D Formularies
After evaluating Part D plans from a medical perspective, Elliott and
colleagues anticipated that dual eligi-
bles might discontinue essential med-
ications because of increased cost
sharing, or might have difficulty
obtaining these medications because of
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Objective: This study assessed the impact of
transition from Medicaid drug coverage to
Medicare Part D on a sample of dually eligible
adults younger than age 65 years with 
disabilities.
Study Design:Telephone survey of employed
adults participating in the Kansas Medicaid
Buy-In program, Working Healthy, about their
experiences in accessing medications after their
transition to Part D. 
Methods: A total of 328 (55%) individuals from a
random sample of 600 agreed to participate in
a survey administered by a university-based
research unit during February and March 2006,
which included 18 questions with yes/no, multiple
choice, and open-ended responses. Participants
resembled other Kansas dual eligibles demo-
graphically and medically, other than having
slightly higher rates of mental illness and lower
rates of mental retardation and some physical
conditions. Participants’ 2004 Medicare and
Medicaid claims data were analyzed to obtain 
an overview of their comorbidities and previous
prescription use. 
Results: Twenty percent of participants reported
difficulty obtaining medications, including drugs
in Part D–protected classes; 13% were required
to switch medications; and 8% stopped taking at
least 1 medication. More than half did not know
they could change plans monthly, potentially
improving their access to medications.
Conclusion:The high incidence of access prob-
lems despite Centers for Medicare & Medicaid
Services (CMS) safeguards points to the need
for ongoing monitoring of Part D. If the problems
persist, CMS must be willing to modify the program
and/or better enforce the rules already in place
to avoid adverse outcomes for beneficiaries with
disabilities.
(Am J Manag Care. 2007;13:14-18)
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formulary restrictions.4 Hoadley and col-
leagues found that “some plans do not
cover the drugs that would be expected
if they were following these (CMS) guide-
lines without any exceptions.”5 In a 50-
state survey of Medicaid officials,
researchers found “failure of some plans to
adhere to the CMS transition plan
requirements or failing to cover all or sub-
stantially all of the drugs in the 6 protect-
ed categories.”6
The Department of Health and Hu-
man Services, Office of the Inspector
General (OIG) investigated the extent
to which Part D formularies include
200 drugs commonly used by dual eligi-
bles under Medicaid.7 The OIG found
that some drugs in protected classes
were not covered by as many as 41% of
the formularies. Twenty-one drugs
commonly used by dual eligibles were
not covered by at least 25% of formula-
ries and, in some cases, up to 57% of
formularies.
EARLY SNAPSHOT OF 
TRANSITION FOR
YOUNGER DUAL 
ELIGIBLES
Sample
Survey participants consisted of 328
(55%) working adults from a random sam-
ple of 600 dually eligible enrollees in
Kansas’s Medicaid Buy-In program,
Working Healthy. Survey participants
were more likely to live in an urban/semiur-
ban area and had slightly higher rates of
mental illness than the sample population,
but were otherwise demographically com-
parable. 
Participants’ demographic and comor-
bidity profiles were comparable with those
of a random sample of 1375 other dually
eligible Kansas Medicaid beneficiaries
with disabilities. Participants had some-
what higher rates of serious mental ill-
nesses (psychotic disorders and major
depression) and lower rates of mental
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n Table 1. Principal Diagnoses of Dually Eligible Kansas Medicare
Beneficiaries* 
Other Kansas
Survey Dual Eligibles
Participants Age <65 Years
Principal Diagnoses (ICD-9 Category) (n = 328) (n = 1375)
HIV infection (042) 0.6 0.4
Malignant neoplasms (140-209, 230-239) 4.6 4.9
Endocrine diseases
Diabetes (250) 12.5 15.7
Hyperlipidemia (272)† 7.3 3.8
Thyroid (240-246) 4.9 4.5
Blood/blood-forming organ diseases (280-289) 3.4 5.2
Mental disorders
Organic psychotic conditions (290-294)† 0.6 2.3
Schizophrenia (295)† 26.5 12.2
Other psychoses (296-299)† 25.0 19.1
Neurotic disorders, depression (300-316) 18.6 22.0
Mental retardation (317-319)† 1.2 6.5
Nervous system and sense-organ diseases
Disorders of the eye and adnexa (360-379) 21.0 24.0
Disorders of the ear (380-389) 8.8 10.6
Multiple sclerosis (340-341) 0.6 1.5
Cerebral palsy and related syndromes (342-344)† 0.9 2.8
Circulatory system diseases
Hypertensive disease (401-405) 10.4 13.5
Ischemic heart disease, myocardial 0.6 2.1
infarctions (410-414)
Heart disease, heart failure (420-429)† 3.4 9.8
Cerebrovascular disease (430-438)† 1.2 3.3
Respiratory system diseases
Asthma (493)† 7.0 4.3
Chronic obstructive pulmonary disease (491-492)† 0.9 3.1
Digestive system diseases (530-537) 7.0 10.1
Chronic renal disease (580-589)† 0.6 4.0
Skin and subcutaneous tissue diseases (680-710) 15.2 16.0
Musculoskeletal system and connective tissue diseases
Systemic and inflammatory arthropathies (710-714) 2.7 2.2
Osteoarthritis and other joint disorders (715-719) 17.1 18.4
Rheumatism, excluding the back (725-729) 13.7 15.5
Dorsopathies (720-724) 13.4 14.7
Osteopathies, chondropathies, and acquired 4.3 5.8
musculoskeletal deformities (730-739)
Digestive system diseases (530-537) 7.0 10.1
*Data are from the Kansas Medicaid Management Information System, 2004 (survey partici-
pants), and 2001-2002 (other dually eligible disabled individuals).
†P ≤ .05. 
Individuals may have reported multiple principal diagnoses. 
ICD-9 indicates International Classification of Diseases, Ninth Revision.
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retardation and physical conditions such as cerebral palsy,
respiratory disease, and heart disease, but were otherwise sim-
ilar to other dually eligible Kansas Medicaid beneficiaries
(Table 1).
Participants were 57% female, with a mean age of 47.3
years. Race was reported as 89% white, 5% African Ameri-
can, 5% Native American, and less than 1% Asian and
other races; 3% of participants reported Hispanic ethnicity.
Demographically, this group closely resembled the general
population of Kansas dual eligibles with disabilities, with
slightly fewer African American and other races represent-
ed.8 Participants lived in both urban and rural communities
similar to the state’s general population.
Methods
Telephone interviews were conducted by a university-
based research unit during February and March 2006. Partici-
pation in the survey was both voluntary and confidential.
Each participant received a $10 stipend. An institutional
review board approved the study. Administrative data on
participants were obtained from calendar year 2004
Medicaid claims files, whereas data for other dual eligibles
were from 2001-2002 Medicaid claims files. Comorbidity data 
were obtained by aggregating International Classification of 
Diseases, Ninth Revision, codes of the primary diagnosis by 
3-digit classes.
Instrument
The survey included 18 questions with yes/no, multiple
choice, and open-ended responses. The full survey is available
from the authors on request.
KEY FINDINGS
Participants experienced 2 major types of issues in the
months immediately after implementation of Part D: (1) lim-
ited access to medications and (2) limited knowledge of rules
and regulations. 
Access Limitations
Despite all the preemptive policies to ensure uninterrupted
therapies, 20% (66/328) of participants had problems getting
prescriptions filled. Moreover, 8% (26/328) reported they
stopped taking at least 1 medication due to access issues. Of the
56 respondents who explained their difficulties, 46% (25/56)
had to pay either the entire cost of the drug or more out-of-
pocket costs than they did under Medicaid; 34% (19/56)
needed drugs that were not in the formularies; and 11% (6/56)
had difficulty with dosage or refill timing restrictions. 
More than one third (15/41) of respondents who identified
the drug(s) they could not obtain experienced difficulty
acquiring Part D protected class drugs; 4 respondents experi-
enced difficulty getting more than 1 protected drug (Table 2).
Nine respondents reported problems obtaining antidepres-
sants; 5 reported limited access to antipsychotics; 4 had dif-
ficulty getting anticonvulsants; and 1 reported trouble
acquiring an immunosuppressant. Eleven (27%) respondents
reported trouble getting benzodiazepines, a drug class not cov-
ered by Part D yet covered by Kansas Medicaid, indicating
high need for these drugs and lack of information about navi-
gating between Medicaid and Part D. Serious, even life-
threatening withdrawal symptoms can result from abrupt
cessation in a long-term user.4
Fourteen percent (45/328) of survey participants indicat-
ed that they were required to get documentation to continue
their prescriptions. More than half of these participants
reported that documentation took more than 5 days, threat-
ening or interrupting therapy.
Many participants experienced limited access to drugs
under the assigned plans. In fact, 23% (77/328) changed
plans. Forty-four percent (34/77) of those who switched plans
did so because their assigned plan did not meet their needs or
cover needed medications, and 18% (14/77) switched because
their local pharmacy did not accept the plan to which they
had been assigned. 
Thirteen percent (43/328) of participants reported being
required to change a medication. Sixty percent (26/43) of
these respondents were required to switch to a generic form.
Forty-four percent (19/43) were switched to a completely dif-
ferent drug or to a different formulation (eg, from an extend-
ed-release form to a regular form). Among the 35 respondents
who could recall specific drugs from which they were required
to switch, 37% (13/35) of the changes were in a protected
drug class.
Knowledge
More than half of the participants did not know that, as
full-benefit dual eligibles, they could change plans month-
ly, if needed. Although some knew they could change
plans, they did not know how to do so, nor whom to ask
for help.
DISCUSSION AND 
CONCLUSIONS
Despite the small, geographically limited sample, this study
is important to policy makers and plan sponsors as an early
warning of possible trends. As high users of psychotropic
medications, these participants
serve as a barometer for the success
of policies to protect continued
access to certain classes of critical
drugs. Although some of our find-
ings appear to be transition relat-
ed, they have the potential to
seriously disrupt individuals’ drug
regimens and long-term well-
being. For example, many individ-
uals who were not required to
make copayments under
Medicaid were suddenly faced
with multiple copayments and no
protection if they were unable to
meet them. Under Part D, the
copayments are indexed and likely
to rise each year, making the
copayments a long-term issue of
great importance. Other issues,
such as lack of knowledge about
the ability to change plans, can be
addressed through additional out-
reach and educational efforts.
However, the ability to better
negotiate different plans is of little
relevance if one’s local pharmacy
accepts only a single plan. As one
participant noted, Part D is diffi-
cult when one lives in a small
town, especially when one has a
disability and, often, transporta-
tion difficulties. 
The fact that numerous people
were unable to obtain medications
included in protected drug classes
is especially troubling and may
have long-term implications. Further, drug substitutions that
make economic sense may have therapeutic implications for
people with disabilities (eg, those who need assistance taking
medication may not have this assistance available multiple
times throughout the day). Physical and cognitive limitations
may make extended-release forms the only effective modality
and may make the difference between the ability to live in the
community and the necessity of being institutionalized.
In combination, the barriers to access cited by survey par-
ticipants may result in the inability to get needed medications.
Indeed, 8% of our sample had completely stopped taking at
least 1 medication since Part D implementation. 
The Future of Part D
Continued monitoring of Part D in the coming months
and years is imperative. As state initiatives have emerged to
fill the gaps in coverage left in the wake of Part D imple-
mentation, it is important not to lose sight of what can be
done on a federal level to improve Part D. If the issues iden-
tified here persist, CMS must implement remedies. At the
very least, Part D should maintain a level of coverage com-
mensurate with that received by dual eligibles under
Medicaid.
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n Table 2. Difficulties Reported by Dual-Eligible Survey Participants in
Obtaining Medications During Transition to Part D*
Reports of   
Difficulty Percentage of Percentage of
Obtaining Reports Respondents 
Drug Class Medication (n = 67) (n = 41)
Part D–protected Drugs
Antidepressant† 9 13.4 22.0
Antipsychotic‡ 5 7.5 12.2
Anticonvulsant§ 4 6.0 9.8
Immunosuppressant|| 1 1.5 2.4
Other Part D Drugs
Analgesic 6 9.0 14.6
Antiulcer 5 7.5 12.2
Cardiovascular 4 6.0 9.8
Central nervous system stimulant 4 6.0 9.8
Antihistamine 2 3.0 4.9
Thyroid 2 3.0 4.9
Asthma/anti-inflammatory 2 3.0 4.9
Anxiolytic 1 1.5 2.4
Other Part D¶ 6 9.0 19.2
Non–Part D Drugs
Benzodiazepines 11 16.4 26.8
Nonprescription 2 3.0 4.9
Barbiturate 1 1.5 2.4
Erectile dysfunction drug 1 1.5 2.4
Vitamin 1 1.5 2.4
Total 67 100.0 100.0
*Respondents were permitted to report multiple medications.
†Antidepressants included Lexapro, Cymbalta, Prozac, Ludiomil, Paxil, and Tofranil. 
‡Antipsychotics included Abilify, Geodon, Zyprexa, Clozaril, and Lithium. 
§Anticonvulsants included Topamax, Neurontin, and Trileptal. 
||Immunosuppressants included Imuran. 
¶Other included drug classes: antibiotic, muscle relaxant, antispasmodic, migraine agent, sleep
agent, and pituitary hormone.
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n Take-away Points
Problems experienced by dual eligibles with disabilities during transi-
tion to Part D are an early warning of possible trends for other
Medicare recipients.
n Beneficiary access to medications was limited by plan availability,
restrictive formularies, higher out-of-pocket costs, and documentation
delays.
n One in 5 beneficiaries were unable to obtain certain medications,
including those in CMS-protected drug classes.
n One in 12 beneficiaries stopped taking at least 1 medication due to
Part D transition barriers.
